FDA clearances and approvals, off-label use, scope-of-practice rules, and how to read a 510(k) summary without trusting the marketing wrapper.
No exosome product has FDA approval for any aesthetic use. Here is what that means for patients and what to ask before booking a treatment.
A buyer due-diligence guide for clinics evaluating injector-assist devices — covering regulatory status, consumable compatibility, IFU, sterility, warranty, training,…
How aesthetic clinics should use hypochlorous acid (HOCl) disinfectants — surface vs. hand vs. instrument use, EPA registration, contact time, and why HOCl cannot…
Travelling to Hong Kong for filler injections adds documentation gaps, follow-up complications, and jurisdictional risks. The GN-00 update helps if you know what to ask…
On 13 May 2026, Hong Kong formally classified injectable dermal fillers as medical devices under MDACS. Here is what that means for filler safety, product legitimacy,…
Hong Kong's GN-00 update classifies dermal fillers as medical devices. Here is how to verify product authenticity, vet clinics, and spot red flags before your filler…
How practices should vet post-procedure adjuncts — scar gels, liquid bandages, cooling sprays — covering claims substantiation, the device/drug/cosmetic boundary, and…
Incident review framework for aesthetic practices covering documentation, root-cause analysis, corrective action, MedWatch reporting, manufacturer escalation, and…
A med spa consultation workflow covering intake forms, medical history screening, contraindication flags, expectation setting, no-treatment decisions, and defensible…
How to build a credentialing and privileging file for new aesthetic injectors, including training verification, competency assessments, emergency drills, and scheduled…